-

Charles River Laboratories to Present at TD Cowen and Barclays Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:

  • TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 9:50 a.m. ET; and
  • Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, at 10:00 a.m. ET.

Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for at least two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories to Present at TD Cowen and Barclays Conferences
Release Versions

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Laboratories Announces Second-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2026 Financial Results...

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call...

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA...
Back to Newsroom